FDA

News

FDA appoints veteran Pazdur to replace Tidmarsh

The FDA has steadied the ship at CDER by naming veteran regulator Richard Pazdur as director, although he was reportedly reluctant to take the job.

Market Access

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.

News

GLP-1s feature in second batch of national priority vouchers

GLP-1 drugs for weight loss, cancer, and rare diseases feature among the latest crop of medicines awarded priority vouchers by the FDA.

News

Dismay as FDA declines to approve Biohaven's ataxia drug

Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, in another sign of a tougher stance by the agency.

R&D

Biotech’s biggest challenge isn’t scientific, but political ...

We speak to James Roosevelt Jr, a longtime healthcare leader, former associate commissioner of social security for retirement policy & grandson of FDR

News

CDER head Tidmarsh 'on leave' and is sued by drugmaker

George Tidmarsh is no longer at the helm of CDER and is facing a lawsuit claiming he abused his position there to harm a former business associate.

FDA appoints veteran Pazdur to replace Tidmarsh

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

GLP-1s feature in second batch of national priority vouchers

Dismay as FDA declines to approve Biohaven's ataxia drug

Biotech’s biggest challenge isn’t scientific, but political ...

CDER head Tidmarsh 'on leave' and is sued by drugmaker

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

FDA

Editor's Picks